Afinitor and Vandetanib drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Afinitor (everolimus) and Vandetanib (vandetanib). Common drug interactions include blood cholesterol increased among females.

The phase IV clinical study analyzes what interactions people have when they take Afinitor and Vandetanib. It is created by eHealthMe based on reports of 48 people who take the same drugs from the FDA, and is updated regularly.

What is Afinitor?

Afinitor has active ingredients of everolimus. It is often used in breast cancer metastatic. eHealthMe is studying from 41,680 Afinitor users. Check the latest studies of Afinitor.

What is Vandetanib?

Vandetanib has active ingredients of vandetanib. eHealthMe is studying from 1,032 Vandetanib users. Check the latest studies of Vandetanib.

On Jul, 19, 2026

48 people who take Afinitor and Vandetanib together, and have interactions are studied.

Afinitor and Vandetanib drug interactions.

What are the common drug interactions of Afinitor and Vandetanib, by gender? *:

female:

Blood cholesterol increased
Facial paralysis (loss of function of face muscle)
Hypophosphataemia (electrolyte disturbance in which there is an abnormally low level of phosphate in the blood)
Ocular hyperaemia (an abnormally large amount of blood in eye)
Alanine aminotransferase increased
Blood triglycerides increased
Flatulence (flatus expelled through the anus)
Gastrooesophageal reflux disease (stomach contents (food or liquid) leak backwards from the stomach into the oesophagus)
Hypophagia (reduced food intake)
Lymphocyte count decreased

male:

n/a

What are the common drug interactions of Afinitor and Vandetanib, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
Ataxia (loss of full control of bodily movements)
Brain stem glioma (cancerous glioma tumour in the brainstem)
Abdominal distension
Hemiparesis (weakness on one side of the body)
Electrocardiogram qt prolonged
Hypertension (high blood pressure)
Hypophosphataemia (electrolyte disturbance in which there is an abnormally low level of phosphate in the blood)
Ocular hyperaemia (an abnormally large amount of blood in eye)
Alanine aminotransferase increased

10-19:

n/a

20-29:

Headache (pain in head)
Insomnia (sleeplessness)
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
Metastases to bone (cancer spreads to bone)
Metastases to central nervous system (cancer spreads to central nervous system)
Metastases to liver (cancer spreads to liver)
Neoplasm progression (growth of tumour)

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

n/a

What are the existing conditions these people have? *

Paraganglion Neoplasm Malignant (paraganglion cancerous tumour): 24 people, 50.00%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 24 people, 50.00%
Brain Stem Glioma (cancerous glioma tumour in the brainstem): 24 people, 50.00%
Phaeochromocytoma (vascular tumour of the adrenal gland): 17 people, 35.42%
Diarrhea: 17 people, 35.42%
Phaeochromocytoma Malignant (cancer of the adrenal gland): 5 people, 10.42%

* Approximation only. Some reports may have incomplete information.

Do you take Afinitor and Vandetanib?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously